Clinical trials: Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily
The purpose of this study is to determine whether an experimental drug known as tadalafil given once daily can reduce the symptoms associated with Benign Prostatic Hyperplasia (straining, urinary frequency, feeling like your…
- Trial name
- NCT00827242
- Testing
- tadalafil
- Where
- 27 sites in United States, Argentina and 3 more
- Volunteers
- 325 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers
The purpose of this study is to evaluate the safety and efficacy of tadalafil when given to men who are currently taking a medication called an alpha blocker for the treatment of benign prostatic hyperplasia (BPH) symptoms (such…
- Trial name
- NCT00848081
- Testing
- Tadalafil
- Where
- 31 sites in United States, Puerto Rico
- Volunteers
- 318 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia, Prostatic Hyperplasia
Extension Study of GI198745 to Treat Benign Prostatic Hyperplasia
The primary objective is to assess the safety of GI198745 0.05mg, 0.5mg, 2.5mg once daily for 52 weeks.
- Trial name
- NCT00969072
- Testing
- GI198745 0.05mg, GI198745 0.5mg, GI198745 2.5mg
- Volunteers
- 121 people
- Sponsor
- GlaxoSmithKline
Prostatic Hyperplasia
ALF-ONE : ALFuzosin ONcE Daily
The aim of the study is to collect, under daily practice conditions, clinical data on the safety profile and the efficacy of a new formulation of alfuzosin administered once daily in patients with lower urinary tract symptoms…
- Trial name
- NCT00280605
- Testing
- Alfuzosin
- Volunteers
- 200 people
- Sponsor
- Sanofi
Benign Prostatic Hyperplasia
Effects of Chronic Use of Doxazosin in Men With Benign Prostatic Hyperplasia
In this study, we investigate the changes of the expression of alpha adrenergic receptor in the prostate tissue during 2-yr medication period in the man with benign prostatic hyperplasia.
- Trial name
- NCT00730418
- Testing
- Doxazosin
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Samsung Medical Center
Prostatic Hyperplasia, Adrenergic Alpha-Antagonists
The Effectiveness of Saw Palmetto and Sanmiaoshan on Benign Prostatic Hyperplasia in Chinese Patients
The purpose of this study is to assess the effect of saw palmetto and sanmiaoshan, on top of alpha blocker, on urinary flow rate and BPH symptoms in patients with BPH.
- Trial name
- NCT00497939
- Testing
- Saw palmetto and sanmiaoshan capsule
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Hospital Authority, Hong Kong
Benign Prostatic Hyperplasia
The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months
A new drug for benign prostatic hyperplasia is used for 9 months to determine its long-term safety.
- Trial name
- NCT00224133
- Testing
- Silodosin
- Where
- 79 sites in United States
- Volunteers
- 661 people
- Sponsor
- Watson Pharmaceuticals
Benign Prostatic Hyperplasia
Transurethral Ventral Wall of Urethra-preserving Enucleation of Prostate
In this study, the investigators designed a randomized and double-blind prospective trial to evaluate the efficiency and safety of the investigators new approach-transurethral ventral wall of urethra-preserving enucleation of…
- Trial name
- NCT01073241
- Testing
- transurethral ventral wall of urethra-preserving enucleation of prostate, transurethral prostatic resection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Southwest Hospital, China
Benign Prostatic Hyperplasia
Temperature Mapping of the Prostate With the Wallterm™ System
To measure intra-prostatic temperatures and evaluate the shape and size of necrotic lesions achieved under the standard treatment protocol in men with benign prostatic hyperplasia (BPH).
- Trial name
- WT-DK-TMW08 (NCT00662350)
- Testing
- The Wallterm™ System
- Where
- Denmark
- Volunteers
- 6 people
- Sponsor
- Pnn Medical A/S
Benign Prostatic Hyperplasia
Saw Palmetto Extract in Benign Prostatic Hyperplasia
The purpose of this study is to test whether an extract of the saw palmetto plant is effective for relieving symptoms of Benign Prostatic Hyperplasia (BPH).
- Trial name
- NCT00037154
- Testing
- Saw Palmetto
- Where
- 2 sites in United States
- Volunteers
- 224 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Benign Prostatic Hyperplasia
Minimally Invasive Surgical Therapy for BPH
The primary objective of this randomized clinical trial is to determine the efficacy and safety of three treatments for benign prostatic hyperplasia (BPH): transurethral needle ablation (TUNA), transurethral microwave therapy…
- Trial name
- MIST (NCT00064649)
- Testing
- Transurethral Microwave Thermotherapy (TUMT), Transurethral Needle Ablation (TUNA) Therapy, Finasteride and Alfuzosin
- Where
- 7 sites in United States
- Volunteers
- 49 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Benign Prostatic Hyperplasia
Study of the Effects of Pomegranate Tablets on Enlarged Prostates
To determine whether pomegranate tablets have a therapeutic effect on Benign Prostatic Hyperplasia.
- Trial name
- NCT00381108
- Testing
- Pomegranate Tablet
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of California, Irvine
Benign Prostatic Hyperplasia
A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.
- Trial name
- NCT00224120
- Testing
- Silodosin
- Where
- 42 sites in United States
- Volunteers
- 462 people
- Sponsor
- Watson Pharmaceuticals
Sexual Dysfunctions in Men With Benign Prostatic Hyperplasia
Clinical Study to Assess the Influence of a Saw Palmetto Preparation in Patients With Benign Prostatic Hyperplasia (BPH) and Sexual Dysfunctions
Assessment in an open trial if a standardized saw palmetto preparation has a positive influence on sexual dysfunctions in patients with BPH and sexual dysfunctions.
- Trial name
- NCT01021267
- Testing
- Saw palmetto berry extract
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- A. Vogel AG
Benign Prostatic Hyperplasia
Long Term Safety of SL77.0499-10 (Alfuzosin) in Patients With BPH
Primary: To assess the safety of SL77.0499-10 10mg administered once daily for one year in patients with lower urinary tract symptoms related to BPH.
- Trial name
- NCT00347061
- Testing
- afuzosin
- Where
- Japan
- Volunteers
- 148 people
- Sponsor
- Sanofi
Prostatic Hyperplasia
Efficacy and Safety of SL77.0499-10 (Alfuzosin) Versus Placebo and Tamsulosin in Japanese Patients With Benign Prostatic Hyperplasia
The primary objective of the study is to demonstrate the superiority of SL77.0499-10 10mg once daily over placebo and the non-inferiority versus tamsulosin hydrochloride after 12 weeks treatment in terms of the efficacy in…
- Trial name
- NCT00399464
- Testing
- alfuzosin
- Where
- Japan
- Volunteers
- 1,177 people
- Sponsor
- Sanofi
Benign Prostatic Hyperplasia
Dose Ranging Study of Alfuzosin in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia
The primary objective is to assess the dose-response relationship of SL77.0499 10 (alfuzosin hydrochloride) 5 mg, 10 mg, 15 mg, and placebo once daily during a 12-week oral administration period for the efficacy in patients with…
- Trial name
- NCT00409357
- Testing
- SL77.0499-10 (alfuzosin hydrochloride)
- Where
- Japan
- Volunteers
- 473 people
- Sponsor
- Sanofi
Benign Prostatic Hyperplasia
Procedure Transurethral Needle Ablation (TUNA) and Hospitalization of Short Duration
The TUNA is a known and already old technique. There exists, in the literature, a certain number of studies showing the long-term effectiveness (5 years), evaluated on the IPS and the flow mictional.This effectiveness is slightly…
- Trial name
- EPURE (NCT00890851)
- Testing
- Transurethral Needle Ablation (TUNA)
- Where
- France
- Volunteers
- 53 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Prostatic Hyperplasia
SAMBA: Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin
Primary Objective: To assess the sexual function improvement from baseline to the end of treatment (Week 24 or premature withdrawal (PW)) with XATRAL 10mg OD.
- Trial name
- NCT00486785
- Testing
- Alfuzosin
- Where
- 4 sites in Colombia, Ecuador and 2 more
- Volunteers
- 431 people
- Sponsor
- Sanofi
Prostatic Hyperplasia
Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin
Primary objective: End-point improvement from baseline in Male Sexual Health Questionnaire Ejaculation domain (MSHQ-EjD)in men with lower urinary tract symptoms (LUTS)suggestive of benign prostatic hyperplasia (BPH) treated for 6…
- Trial name
- SAMBA-Thailand (NCT00401661)
- Testing
- Alfuzosin
- Where
- Thailand
- Volunteers
- 110 people
- Sponsor
- Sanofi